« Previous | Next » | All Messages |  IAGX Message Board Home | recommend post |  Ignore Poster

IAGX News Imagenetix Launches Retail Branding Program; Former Pharmavite Executives To Spearhead Campaign

These products, branded under the name Inflame Away(TM), will be exclusively marketed by Imagenetix and sold directly to leading mass market retailers nationwide.

The retail branding program will be led by two former executives of Pharmavite Corporation, a manufacturer and marketer of vitamins and nutritional supplements.

This program is expected to significantly improve Imagenetix' top- and bottom-line performance.

Specifically, the program will give Imagenetix the opportunity to build consumer demand for Inflame Away(TM) by generating a comprehensive marketing campaign that directly and exclusively supports the brand. Additionally, the program will provide the company with a direct relationship with mass market retailers carrying the brand, facilitate the marketing of future Imagenetix-branded products to these retailers, and strengthen the company's reputation as a provider of efficacious, scientifically proven natural-based products.

Inflame Away(TM), in regular strength and extra strength softgel formulas as well as pain relieving cream formulas, is scheduled to be available at retail outlets by Fall 2006. The products will be supported by a marketing campaign featuring live interactive radio spots, television commercials, celebrity testimonials, online advertising and grassroots promotions in the 50 top markets across the nation.

The former Pharmavite executives, Tom Hall and Frank Sajovic, were responsible for developing and leading the sales and marketing campaign that built that company's Nature Made Vitamins into the premier vitamin brand in the marketplace. Mr. Hall served as vice president of sales for Pharmavite from 1981 through 1996, a time frame in which sales grew significantly for the company. Mr. Sajovic served as Pharmavite's executive vice president for domestic marketing and international sales and marketing for the years 1987 through 1999, during which corporate annual sales grew from $60 million to over $400 million.

"We believe the best way to build long-term shareholder value is to create brand names with loyal consumer following," said Imagenetix chief executive, William P. Spencer. "Under the guidance of highly successful marketers such as Frank Sajovic and Tom Hall, we believe we can establish Inflame Away(TM) as a leading joint health brand and produce superior financial results for Imagenetix."

Mr. Sajovic added: "Consumers are demanding natural products proven by science to be both safe and effective. Imagenetix, with its clinical research program led by Dr. Robert Hesslink, Director of Research, has insured that Inflame Away(TM) meets this high standard."

Celadrin(R), the primary ingredient of Inflame Away(TM), has been shown to provide rapid and significant enhancement of joint health(a), with no reported side effects, in double-blind, placebo-controlled trials published in peer-reviewed medical journals. Regarding Celadrin(R) topical formula, the April 2004 Journal of Rheumatology reported that 100 percent of arthritic subjects experienced less pain and greater range of motion within 30 minutes of applying the product. A second topical study, in the February 2005 Journal of Strength & Conditioning Research, found that knee arthritic participants had 43 percent less pain and improved posture within one week of application.

A Celadrin(R) oral study, published in the February 2002 Journal of Rheumatology, reported that subjects experienced significant improvement in joint flexibility, the ability to walk up and down stairs and the ability to walk extended distances, within 30 days of commencing consumption of the product.(a)

Fifteen other scientific studies have validated Celadrin(R)'s safety and/or efficacy.

Imagenetix will announce news of additional products to be launched under the branding program in the near future.

San Diego-based Imagenetix, Inc., www.imagenetix.net, is developing novel drugs for the treatment of inflammatory diseases. The company also develops and markets natural-based proprietary products, including over-the-counter topical creams and skin care products, for inflammation-related markets. (a) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Safe Harbor Statement

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.